Outset Medical, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 4, 2026, reporting financial results for both the three and nine months ended on that date.

Key Highlights

  • Total revenue of $33.6 million for the three months ended September 30, 2026, up from $29.4 million in the same period of 2025, according to the filing.
  • Net loss of $14.7 million for the third quarter of 2026, compared to a net loss of $17.8 million in Q3 2025, as reported in the condensed statements of operations.
  • Nine-month net loss of $51.6 million for the period ended September 30, 2026, versus a net loss of $62.2 million for the same period in 2025.
  • Accumulated deficit reached $1.223 billion as of September 30, 2026, up from $1.171 billion at December 31, 2025.
  • Total assets of $230.4 million as of September 30, 2026, compared to $264.5 million at December 31, 2025.
  • 18,872,597 shares of common stock outstanding as of November 2, 2026, per the cover page of the filing.
  • Term loan balance of $98.4 million as of September 30, 2026, compared to $96.2 million at December 31, 2025.

Outset Medical's Q3 2026 Revenue Growth and Continued Operating Losses

According to the filing, Outset Medical (NASDAQ:OM) reported total revenue of $33.6 million for the three months ended September 30, 2026, consisting of $23.7 million in product revenue and $9.9 million in service and other revenue. This compares to total revenue of $29.4 million in the third quarter of 2025. For the nine months ended September 30, 2026, total revenue was $93.1 million, up from $90.6 million in the same prior-year period.

The company's gross profit for the third quarter of 2026 was $13.7 million, up from $11.6 million in Q3 2025. For the nine months ended September 30, 2026, gross profit was $39.0 million versus $34.5 million a year earlier. The filing shows that total operating expenses for the third quarter were $25.9 million, compared to $27.4 million in Q3 2025, resulting in a loss from operations of $12.3 million for the quarter, improved from a $15.8 million operating loss in Q3 2025. Net loss per share, basic and diluted, was $(0.78) for Q3 2026 versus $(1.00) for Q3 2025.

As of September 30, 2026, the company reported total stockholders' equity of $83.3 million, down from $127.0 million at December 31, 2025, reflecting the ongoing net losses recorded during the nine-month period. Cash and cash equivalents stood at $33.9 million, and short-term investments were $102.7 million, the filing disclosed. The company also reported finance lease right-of-use assets of $1.6 million as of September 30, 2026, a category that showed no balance at December 31, 2025.

What Was Disclosed

Outset Medical's 10-Q for the quarter ended September 30, 2026 disclosed quarterly and year-to-date revenue, net losses, balance sheet positions, and share counts, including an accumulated deficit of $1.223 billion and a term loan carrying value of $98.4 million.